Biocon Ltd

Biocon Ltd Share Price

Biocon Limited is the first Indian business to produce and sell enzymes to the United States and Europe. It was established in 1978 as Biocon India Private Limited. In 1982, the business established BCZ (BioChemizyme India) to focus on enzyme research and development. In 1990, it expanded its in-house research programme, which was based on a patented solid substrate fermentation technique. In 1996, the business expanded into biopharmaceuticals and statins by using its technical platform. Variations in the global energy landscape, market demand, and regulatory actions are some of the factors that have impacted the Biocon share price history. Biocon share price NSE & BSE can be tracked daily using BlinkX.

Biocon Ltd Business Segments

1. Business Segments: Generics: The firm produces and supplies innovative and economical generic bulk pharmaceuticals and completed formulations.
2. Biosimilars: The firm manages this business through Biocon Biologics Limited (BBL). It is a biosimilars leader engaged in biosimilar development, production, and commercialisation.
3. Innovative Biologics: This business segment is currently developing innovative assets for autoimmune illnesses and cancer. In 2006, the business launched Nimotuzumab, India's first indigenously made monoclonal antibody for head and neck cancer.
4. Research Services: The corporation operates this business through Syngene, a premier organisation that provides integrated discovery research, development, and manufacturing services.

Subsidiaries of Biocon Ltd

• Syngene International Limited: It is a subsidiary of Biocon. The firm offers services like comprehensive drug discovery and development capabilities in chemistry, biology, and vivo & in vitro pharmacology. 
• Syngene USA Inc: It is a completely owned subsidiary of Syngene, founded in 2017. It provides business and sales support services for Syngene's activities in the United States.
• Syngene Scientific Solutions Limited (SSSL): The company is a completely owned subsidiary of Syngene. It specialises in contract research and manufacturing services (CRAMS) and clinical research services.

Biocon Ltd Key Personnel

Kiran Mazumdar-Shaw is the executive chairman of Biocon Limited and Biocon Biologics Limited. She is a first-generation entrepreneur with over 40 years of expertise in biotechnology. She has been the chairman of the Biocon Board of Directors since its creation. For future use, set a Biocon share price target with BlinkX.

Biocon Ltd Corporate Actions

• In 2004, the firm raised Rs. 300 crore through an initial public offering (IPO) to support capital growth goals.
• In 2017, Biocon announced a 2:1 bonus issuance with a record date of June 15, 2017.
• In 2019, the business announced a 1:1 bonus issuance with a record date of June 12, 2019.